Impact  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
Avène  ||| S:10 E:16 ||| NNP
hydrotherapy  ||| S:16 E:29 ||| NN
on  ||| S:29 E:32 ||| IN
the  ||| S:32 E:36 ||| DT
quality  ||| S:36 E:44 ||| NN
of  ||| S:44 E:47 ||| IN
life  ||| S:47 E:52 ||| NN
of  ||| S:52 E:55 ||| IN
atopic  ||| S:55 E:62 ||| NN
and  ||| S:62 E:66 ||| CC
psoriatic  ||| S:66 E:76 ||| JJ
patients  ||| S:76 E:85 ||| NNS
Atopic  ||| S:85 E:92 ||| JJ
dermatitis  ||| S:92 E:103 ||| NN
and  ||| S:103 E:107 ||| CC
psoriasis  ||| S:107 E:117 ||| NNS
engender  ||| S:117 E:126 ||| VBP
a  ||| S:126 E:128 ||| DT
significant  ||| S:128 E:140 ||| JJ
deterioration  ||| S:140 E:154 ||| NN
in  ||| S:154 E:157 ||| IN
patients ||| S:157 E:165 ||| NNS
'  ||| S:165 E:167 ||| POS
quality  ||| S:167 E:175 ||| NN
of  ||| S:175 E:178 ||| IN
life ||| S:178 E:182 ||| NN
.  ||| S:182 E:184 ||| .
Although  ||| S:184 E:193 ||| IN
the  ||| S:193 E:197 ||| DT
efficacy  ||| S:197 E:206 ||| NN
of  ||| S:206 E:209 ||| IN
patient  ||| S:209 E:217 ||| JJ
management  ||| S:217 E:228 ||| NN
at  ||| S:228 E:231 ||| IN
the  ||| S:231 E:235 ||| DT
Avène  ||| S:235 E:241 ||| JJ
hydrotherapy  ||| S:241 E:254 ||| JJ
centre  ||| S:254 E:261 ||| NN
has  ||| S:261 E:265 ||| VBZ
been  ||| S:265 E:270 ||| VBN
demonstrated  ||| S:270 E:283 ||| VBN
by  ||| S:283 E:286 ||| IN
clinical  ||| S:286 E:295 ||| JJ
studies ||| S:295 E:302 ||| NNS
,  ||| S:302 E:304 ||| ,
few  ||| S:304 E:308 ||| JJ
data  ||| S:308 E:313 ||| NNS
relating  ||| S:313 E:322 ||| VBG
to  ||| S:322 E:325 ||| TO
changes  ||| S:325 E:333 ||| NNS
in  ||| S:333 E:336 ||| IN
the  ||| S:336 E:340 ||| DT
quality  ||| S:340 E:348 ||| NN
of  ||| S:348 E:351 ||| IN
life  ||| S:351 E:356 ||| NN
following  ||| S:356 E:366 ||| VBG
therapeutic  ||| S:366 E:378 ||| JJ
management  ||| S:378 E:389 ||| NN
are  ||| S:389 E:393 ||| VBP
available ||| S:393 E:402 ||| JJ
.  ||| S:402 E:404 ||| .
The  ||| S:404 E:408 ||| DT
objective  ||| S:408 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
this  ||| S:421 E:426 ||| DT
study  ||| S:426 E:432 ||| NN
was  ||| S:432 E:436 ||| VBD
to  ||| S:436 E:439 ||| TO
evaluate  ||| S:439 E:448 ||| VB
the  ||| S:448 E:452 ||| DT
short-  ||| S:452 E:459 ||| JJ
and  ||| S:459 E:463 ||| CC
medium-term  ||| S:463 E:475 ||| JJ
effects  ||| S:475 E:483 ||| NNS
of  ||| S:483 E:486 ||| IN
hydrotherapy  ||| S:486 E:499 ||| VBG
not  ||| S:499 E:503 ||| RB
only  ||| S:503 E:508 ||| RB
on  ||| S:508 E:511 ||| IN
the  ||| S:511 E:515 ||| DT
patients ||| S:515 E:523 ||| NNS
'  ||| S:523 E:525 ||| POS
quality  ||| S:525 E:533 ||| NN
of  ||| S:533 E:536 ||| IN
life ||| S:536 E:540 ||| NN
,  ||| S:540 E:542 ||| ,
but  ||| S:542 E:546 ||| CC
also  ||| S:546 E:551 ||| RB
on  ||| S:551 E:554 ||| IN
the  ||| S:554 E:558 ||| DT
quality  ||| S:558 E:566 ||| NN
of  ||| S:566 E:569 ||| IN
life  ||| S:569 E:574 ||| NN
of  ||| S:574 E:577 ||| IN
the  ||| S:577 E:581 ||| DT
parents  ||| S:581 E:589 ||| NNS
of  ||| S:589 E:592 ||| IN
the  ||| S:592 E:596 ||| DT
treated  ||| S:596 E:604 ||| JJ
children ||| S:604 E:612 ||| NNS
.  ||| S:612 E:614 ||| .
In  ||| S:614 E:617 ||| IN
this  ||| S:617 E:622 ||| DT
6-month  ||| S:622 E:630 ||| JJ
longitudinal  ||| S:630 E:643 ||| JJ
observational  ||| S:643 E:657 ||| JJ
study ||| S:657 E:662 ||| NN
,  ||| S:662 E:664 ||| ,
adult  ||| S:664 E:670 ||| NN
( ||| S:670 E:671 ||| -LRB-
n  ||| S:671 E:673 ||| CD
=  ||| S:673 E:675 ||| SYM
174 ||| S:675 E:678 ||| CD
)  ||| S:678 E:680 ||| -RRB-
and  ||| S:680 E:684 ||| CC
paediatric  ||| S:684 E:695 ||| NNS
( ||| S:695 E:696 ||| -LRB-
n  ||| S:696 E:698 ||| CD
=  ||| S:698 E:700 ||| SYM
212 ||| S:700 E:703 ||| CD
)  ||| S:703 E:705 ||| -RRB-
atopic  ||| S:705 E:712 ||| JJ
patients  ||| S:712 E:721 ||| NNS
and  ||| S:721 E:725 ||| CC
psoriatic  ||| S:725 E:735 ||| JJ
patients  ||| S:735 E:744 ||| NNS
( ||| S:744 E:745 ||| -LRB-
n  ||| S:745 E:747 ||| CD
=  ||| S:747 E:749 ||| SYM
262 ||| S:749 E:752 ||| CD
)  ||| S:752 E:754 ||| -RRB-
had  ||| S:754 E:758 ||| VBD
to  ||| S:758 E:761 ||| TO
complete  ||| S:761 E:770 ||| VB
questionnaires  ||| S:770 E:785 ||| VBN
relating  ||| S:785 E:794 ||| VBG
to  ||| S:794 E:797 ||| TO
the  ||| S:797 E:801 ||| DT
quality  ||| S:801 E:809 ||| NN
of  ||| S:809 E:812 ||| IN
life  ||| S:812 E:817 ||| NN
at  ||| S:817 E:820 ||| IN
the  ||| S:820 E:824 ||| DT
beginning  ||| S:824 E:834 ||| NN
( ||| S:834 E:835 ||| -LRB-
D0 ||| S:835 E:837 ||| NNP
)  ||| S:837 E:839 ||| -RRB-
and  ||| S:839 E:843 ||| CC
after  ||| S:843 E:849 ||| IN
3  ||| S:849 E:851 ||| CD
weeks  ||| S:851 E:857 ||| NNS
hydrotherapy  ||| S:857 E:870 ||| VBP
( ||| S:870 E:871 ||| -LRB-
W3 ||| S:871 E:873 ||| NNP
) ||| S:873 E:874 ||| -RRB-
,  ||| S:874 E:876 ||| ,
and  ||| S:876 E:880 ||| CC
then ||| S:880 E:884 ||| RB
,  ||| S:884 E:886 ||| ,
3  ||| S:886 E:888 ||| CD
( ||| S:888 E:889 ||| -LRB-
M3 ||| S:889 E:891 ||| NNP
)  ||| S:891 E:893 ||| -RRB-
and  ||| S:893 E:897 ||| CC
6  ||| S:897 E:899 ||| CD
months  ||| S:899 E:906 ||| NNS
( ||| S:906 E:907 ||| -LRB-
M6 ||| S:907 E:909 ||| NNP
)  ||| S:909 E:911 ||| -RRB-
later ||| S:911 E:916 ||| RB
.  ||| S:916 E:918 ||| .
The  ||| S:918 E:922 ||| DT
dermatology  ||| S:922 E:934 ||| JJ
life  ||| S:934 E:939 ||| NN
quality  ||| S:939 E:947 ||| NN
index  ||| S:947 E:953 ||| NN
( ||| S:953 E:954 ||| -LRB-
DLQI ||| S:954 E:958 ||| NNP
)  ||| S:958 E:960 ||| -RRB-
and  ||| S:960 E:964 ||| CC
the  ||| S:964 E:968 ||| DT
Short-Form-12  ||| S:968 E:982 ||| NNP
Health  ||| S:982 E:989 ||| NNP
Survey  ||| S:989 E:996 ||| NNP
( ||| S:996 E:997 ||| -LRB-
SF-12 ||| S:997 E:1002 ||| NNP
)  ||| S:1002 E:1004 ||| -RRB-
generic  ||| S:1004 E:1012 ||| JJ
questionnaire  ||| S:1012 E:1026 ||| NN
were  ||| S:1026 E:1031 ||| VBD
given  ||| S:1031 E:1037 ||| VBN
to  ||| S:1037 E:1040 ||| TO
adult  ||| S:1040 E:1046 ||| VB
patients ||| S:1046 E:1054 ||| NNS
.  ||| S:1054 E:1056 ||| .
The  ||| S:1056 E:1060 ||| DT
children ||| S:1060 E:1068 ||| NNS
's  ||| S:1068 E:1071 ||| POS
dermatological  ||| S:1071 E:1086 ||| JJ
life  ||| S:1086 E:1091 ||| NN
quality  ||| S:1091 E:1099 ||| NN
index  ||| S:1099 E:1105 ||| NN
( ||| S:1105 E:1106 ||| -LRB-
CDLQI ||| S:1106 E:1111 ||| NNP
)  ||| S:1111 E:1113 ||| -RRB-
was  ||| S:1113 E:1117 ||| VBD
given  ||| S:1117 E:1123 ||| VBN
to  ||| S:1123 E:1126 ||| TO
paediatric  ||| S:1126 E:1137 ||| VB
patients ||| S:1137 E:1145 ||| NNS
,  ||| S:1145 E:1147 ||| ,
and  ||| S:1147 E:1151 ||| CC
the  ||| S:1151 E:1155 ||| DT
SF-12  ||| S:1155 E:1161 ||| NN
to  ||| S:1161 E:1164 ||| TO
their  ||| S:1164 E:1170 ||| PRP$
parents ||| S:1170 E:1177 ||| NNS
.  ||| S:1177 E:1179 ||| .
At  ||| S:1179 E:1182 ||| IN
D0 ||| S:1182 E:1184 ||| NNP
,  ||| S:1184 E:1186 ||| ,
the  ||| S:1186 E:1190 ||| DT
DLQI  ||| S:1190 E:1195 ||| NNP
score  ||| S:1195 E:1201 ||| NN
was  ||| S:1201 E:1205 ||| VBD
29.7  ||| S:1205 E:1210 ||| CD
±  ||| S:1210 E:1212 ||| CD
20.1  ||| S:1212 E:1217 ||| CD
and  ||| S:1217 E:1221 ||| CC
26.9  ||| S:1221 E:1226 ||| CD
±  ||| S:1226 E:1228 ||| CD
18.9  ||| S:1228 E:1233 ||| CD
for  ||| S:1233 E:1237 ||| IN
atopic  ||| S:1237 E:1244 ||| NN
and  ||| S:1244 E:1248 ||| CC
psoriatic  ||| S:1248 E:1258 ||| JJ
patients ||| S:1258 E:1266 ||| NNS
,  ||| S:1266 E:1268 ||| ,
respectively ||| S:1268 E:1280 ||| RB
.  ||| S:1280 E:1282 ||| .
At  ||| S:1282 E:1285 ||| IN
W3 ||| S:1285 E:1287 ||| NNP
,  ||| S:1287 E:1289 ||| ,
this  ||| S:1289 E:1294 ||| DT
score  ||| S:1294 E:1300 ||| NN
had  ||| S:1300 E:1304 ||| VBD
decreased  ||| S:1304 E:1314 ||| VBN
significantly  ||| S:1314 E:1328 ||| RB
to  ||| S:1328 E:1331 ||| TO
reach  ||| S:1331 E:1337 ||| VB
16.8  ||| S:1337 E:1342 ||| CD
±  ||| S:1342 E:1344 ||| CD
14.9  ||| S:1344 E:1349 ||| CD
( ||| S:1349 E:1350 ||| -LRB-
P  ||| S:1350 E:1352 ||| NNP
< ||| S:1352 E:1354 ||| SYM
0.01 ||| S:1354 E:1358 ||| CD
)  ||| S:1358 E:1360 ||| -RRB-
and  ||| S:1360 E:1364 ||| CC
10.0  ||| S:1364 E:1369 ||| CD
±  ||| S:1369 E:1371 ||| CD
10.5  ||| S:1371 E:1376 ||| CD
( ||| S:1376 E:1377 ||| -LRB-
P  ||| S:1377 E:1379 ||| NNP
< ||| S:1379 E:1381 ||| SYM
0.001 ||| S:1381 E:1386 ||| NNP
)  ||| S:1386 E:1388 ||| -RRB-
for  ||| S:1388 E:1392 ||| IN
atopic  ||| S:1392 E:1399 ||| NN
and  ||| S:1399 E:1403 ||| CC
psoriatic  ||| S:1403 E:1413 ||| JJ
patients ||| S:1413 E:1421 ||| NNS
,  ||| S:1421 E:1423 ||| ,
respectively ||| S:1423 E:1435 ||| RB
.  ||| S:1435 E:1437 ||| .
The  ||| S:1437 E:1441 ||| DT
DLQI  ||| S:1441 E:1446 ||| NNP
scores  ||| S:1446 E:1453 ||| NNS
at  ||| S:1453 E:1456 ||| IN
M3  ||| S:1456 E:1459 ||| NNP
and  ||| S:1459 E:1463 ||| CC
M6  ||| S:1463 E:1466 ||| NNP
were  ||| S:1466 E:1471 ||| VBD
20.7  ||| S:1471 E:1476 ||| CD
±  ||| S:1476 E:1478 ||| CD
16.4  ||| S:1478 E:1483 ||| CD
and  ||| S:1483 E:1487 ||| CC
23.1  ||| S:1487 E:1492 ||| CD
±  ||| S:1492 E:1494 ||| CD
18.8  ||| S:1494 E:1499 ||| CD
for  ||| S:1499 E:1503 ||| IN
atopic  ||| S:1503 E:1510 ||| JJ
patients  ||| S:1510 E:1519 ||| NNS
and  ||| S:1519 E:1523 ||| CC
18.8  ||| S:1523 E:1528 ||| CD
±  ||| S:1528 E:1530 ||| CD
16.7  ||| S:1530 E:1535 ||| CD
and  ||| S:1535 E:1539 ||| CC
21.9  ||| S:1539 E:1544 ||| CD
±  ||| S:1544 E:1546 ||| CD
19.6  ||| S:1546 E:1551 ||| CD
for  ||| S:1551 E:1555 ||| IN
psoriatic  ||| S:1555 E:1565 ||| JJ
patients  ||| S:1565 E:1574 ||| NNS
and  ||| S:1574 E:1578 ||| CC
remained  ||| S:1578 E:1587 ||| VBD
significantly  ||| S:1587 E:1601 ||| RB
lower  ||| S:1601 E:1607 ||| JJR
in  ||| S:1607 E:1610 ||| IN
comparison  ||| S:1610 E:1621 ||| NN
with  ||| S:1621 E:1626 ||| IN
D0  ||| S:1626 E:1629 ||| CD
values  ||| S:1629 E:1636 ||| NNS
( ||| S:1636 E:1637 ||| -LRB-
P  ||| S:1637 E:1639 ||| NNP
< ||| S:1639 E:1641 ||| SYM
0.05 ||| S:1641 E:1645 ||| CD
) ||| S:1645 E:1646 ||| -RRB-
.  ||| S:1646 E:1648 ||| .
A  ||| S:1648 E:1650 ||| DT
3-week  ||| S:1650 E:1657 ||| JJ
course  ||| S:1657 E:1664 ||| NN
of  ||| S:1664 E:1667 ||| IN
treatment  ||| S:1667 E:1677 ||| NN
at  ||| S:1677 E:1680 ||| IN
the  ||| S:1680 E:1684 ||| DT
Avène  ||| S:1684 E:1690 ||| JJ
hydrotherapy  ||| S:1690 E:1703 ||| NNS
centre  ||| S:1703 E:1710 ||| VBP
significantly  ||| S:1710 E:1724 ||| RB
improved  ||| S:1724 E:1733 ||| VBN
the  ||| S:1733 E:1737 ||| DT
quality  ||| S:1737 E:1745 ||| NN
of  ||| S:1745 E:1748 ||| IN
life  ||| S:1748 E:1753 ||| NN
of  ||| S:1753 E:1756 ||| IN
patients  ||| S:1756 E:1765 ||| NNS
suffering  ||| S:1765 E:1775 ||| VBG
from  ||| S:1775 E:1780 ||| IN
skin  ||| S:1780 E:1785 ||| NN
diseases ||| S:1785 E:1793 ||| NNS
.  ||| S:1793 E:1795 ||| .
This  ||| S:1795 E:1800 ||| DT
improvement  ||| S:1800 E:1812 ||| NN
persisted  ||| S:1812 E:1822 ||| VBD
3  ||| S:1822 E:1824 ||| CD
and  ||| S:1824 E:1828 ||| CC
6  ||| S:1828 E:1830 ||| CD
months  ||| S:1830 E:1837 ||| NNS
after  ||| S:1837 E:1843 ||| IN
management  ||| S:1843 E:1854 ||| NN
by  ||| S:1854 E:1857 ||| IN
hydrotherapy ||| S:1857 E:1869 ||| NN
.  ||| S:1869 E:1871 ||| .
